apollo
Banner
logo
Introducing Our Latest Arrival!
Pivikto 200 mg/50 mg Tablet 28's

Pivikto 200 mg/50 mg Tablet 28's

Prescription drug
 Trailing icon

Composition

ALPELISIB-250MG

Manufacturer/Marketer

Medicines India

Consume Type

ORAL

Return Policy

Not Returnable

Expires on or after

Jan-25

About Pivikto 200 mg/50 mg Tablet 28's

Pivikto 200 mg/50 mg Tablet 28's belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.

Pivikto 200 mg/50 mg Tablet 28's contains Alpelisib. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

To treat your condition effectually, continue using Pivikto 200 mg/50 mg Tablet 28's for as long as your doctor has prescribed it. The most common side effects include rash, decreased appetite, weight loss, nausea, mouth sores, hair loss, tiredness and weakness, vomiting, changes in certain blood tests, allergic reactions, skin reactions, high blood sugar levels, lung problems, and diarrhea. You should talk to your doctor if you persistently experience these side effects.

Avoid taking Pivikto 200 mg/50 mg Tablet 28's if you are allergic to it. It is not recommended for use in pregnancy. Lactating women do not breastfeed during treatment with Pivikto 200 mg/50 mg Tablet 28's and for one week after the last dose. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.

Uses of Pivikto 200 mg/50 mg Tablet 28's

Treatment of Advanced or metastatic breast cancer

Medicinal Benefits

Pivikto 200 mg/50 mg Tablet 28's contains Alpelisib, which belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.

Directions for Use

Pivikto 200 mg/50 mg Tablet 28's should be swallowed as a whole with a glass of water. Do not crush, chew, or break the tablets. The doctor determines the dose and duration based on your health condition.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Pivikto 200 mg/50 mg Tablet 28's

  • Rash
  • Decreased appetite
  • Weight loss
  • Nausea
  • Mouth sores
  • Hair loss
  • Tiredness and weakness
  • Vomiting
  • Changes in certain blood tests
  • Severe allergic reactions
  • High blood sugar levels
  • Lung problems
  • Diarrhea

Drug Warnings

It is not advised during pregnancy, nursing, or for children or young adults under 18. Before taking the Pivikto 200 mg/50 mg Tablet 28's, inform your doctor about all your medical conditions (especially lung infections, diarrhoea, diabetics, kidney or liver impairment), sensitivities or allergic conditions, and all medications you use. Consult your doctor right away if you become pregnant while taking Pivikto 200 mg/50 mg Tablet 28's. Exposure of an unborn child to this medication could cause congenital disabilities, so you should not become pregnant or father a child while on this medication. Effective birth control is required throughout treatment and at least one week after treatment. You should not breastfeed while taking this medication for two weeks after your last dose.

Drug Interactions

Drug-Drug Interactions: Pivikto 200 mg/50 mg Tablet 28's may interact with anticancer medications (e.g. Apalutamide), anticonvulsant medication (e.g. carbamazepine), anticoagulant medication (e.g. edoxaban), antiepileptic medications (e.g. primidone).

Drug-Food Interactions: Avoid the consumption of alcoholic beverages.

Drug-Disease Interactions: Pivikto 200 mg/50 mg Tablet 28's interacts with disease conditions, including cutaneous manifestations (skin inflammation), diabetes, diarrhoea, osteonecrosis of the jaw (a condition where the jawbone is exposed and not covered by gums), pneumonitis (inflammation in your lung tissues) and renal impairment.

Drug-Drug Interactions Checker List

  • APALUTAMIDE
  • CARBAMAZEPINE
  • EDOXABAN
  • PRIMIDONE

Habit Forming

No

Diet & Lifestyle Advise

  • After your treatment begins, several dietary adjustments can help you control side effects.
  • Anyone suffering from a chronic illness, including cancer, should consume foods high in protein, healthy fats, whole grains, and vitamins and minerals.
  • Plant-based proteins are among the greatest meals during chemotherapy or other cancer treatments. They have the highest concentrations of vitamins and minerals, such as nuts, seeds, beans and legumes.
  • Eat a healthy diet and exercise regularly to maintain proper weight.
  • Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, and herbs.
  • De-stress yourself by meditating, reading books, taking a warm bubble bath or listening to soothing music.
  • Performing yoga may also help in improving both physical and mental health.
  • Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
  • Get optimal sleep; rest well.
  • Avoid smoking and alcohol consumption.
  • Avoid fast food, fried food, processed meats, refined carbs and added sugars.

Special Advise

  • Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to Pivikto 200 mg/50 mg Tablet 28's.
  • Pregnancy testing is recommended prior to starting treatment with Pivikto 200 mg/50 mg Tablet 28's.
  • Do not donate Sperm throughout treatment and at least one week after treatment.

Disease/Condition Glossary

Breast cancer: Breast cancer is a type of cancer that develops in breast cells stimulated by a female sex hormone called estrogen. Breast cancer may form in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and the fatty tissue or the fibrous connective tissue within the breast. The tumour cells invade other healthy breast cells and travel to lymph nodes, a primary pathway for the cancer cells to move to other body parts. Symptoms of breast cancer include a lump in the breast or tissue thickening, which feels different than the normal surrounding tissues, breast pain, redness, swelling, and nipple discharge other than breast milk.

Metastatic breast cancer, also called stage IV breast cancer, has spread to another part of the body, most commonly the bones, lungs, brain, or liver. The process of cancer spreading is called metastasis. Metastasis happens when cancer cells break away from the original tumour in the breast and travel to other parts of the body. These cancer cells travel through the bloodstream or the lymphatic system.

bannner image

Alcohol

Caution

Avoid alcohol consumption while on treatment with Pivikto 200 mg/50 mg Tablet 28's.

bannner image

Pregnancy

Unsafe

Pivikto 200 mg/50 mg Tablet 28's should not be used during pregnancy. So, inform your doctor if you are pregnant or suspect pregnancy. You or your partner must use a reliable form of contraception to prevent pregnancy while taking these medications.

bannner image

Breast Feeding

Caution

Lactating women should not breastfeed throughout Pivikto 200 mg/50 mg Tablet 28's treatment and for one week following the final dosage.

bannner image

Driving

Caution

Pivikto 200 mg/50 mg Tablet 28's does not influence the ability to drive or use machines. However, go only if you are alert, as the Pivikto 200 mg/50 mg Tablet 28's may cause weakness or tiredness in some people.

bannner image

Liver

Caution

Limited information is available. Inform your doctor before taking the Pivikto 200 mg/50 mg Tablet 28's if you have had a liver impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.

bannner image

Kidney

Caution

No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr 30 to < 90 mL/min). The effect of severe renal impairment (CLcr < 30 mL/min) on alpelisib is unknown. So, inform your doctor before taking the Pivikto 200 mg/50 mg Tablet 28's if you have had a kidney impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.

bannner image

Children

Unsafe

Safety and effectiveness in patients below the age of 18 years have not been established. Hence, use is not recommended.

Country of origin

Switzerland
Other Info -

Author Details

Doctor imageWe provide you with authentic, trustworthy and relevant information

FAQs

Pivikto 200 mg/50 mg Tablet 28's contains Alpelisib. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.
Hyperglycemia is common with Pivikto 200 mg/50 mg Tablet 28's and can be severe. Your healthcare provider will monitor your blood sugar levels before you start and during treatment with Pivikto 200 mg/50 mg Tablet 28's. Your healthcare provider may monitor your blood sugar levels more often if you have a history of Type 2 diabetes. Tell your healthcare provider right away if you develop symptoms of hyperglycemia, including excessive thirst, dry mouth, more frequent urination than usual or a higher amount of urine than normal and increased appetite with weight loss.
It is critical to understand that Alpelisib is not a traditional chemotherapy drug and functions in a different manner. It works by specifically targeting cancer cells and preventing their growth and spread.
While taking Pivikto 200 mg/50 mg Tablet 28's, make sure you visit your doctor at all the appointments to ensure that treatment works. Regular monitoring of blood and lipid tests and weight checks are required. An effective way of contraception should be used by both men and women while taking the Pivikto 200 mg/50 mg Tablet 28's.
Based on findings from animal studies, Pivikto 200 mg/50 mg Tablet 28's may impair fertility in males and females of reproductive potential. Discuss the risks of taking this medication with your doctor.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.

Add to Cart